Navigation Links
Medicare Administrator Establishes Reimbursement Coding Policy for Agendia's Breast Cancer Recurrence Test MammaPrint(R)
Date:12/1/2009

HUNTINGTON BEACH, California and AMSTERDAM, December 1 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, announced today that Palmetto GBA, California's Part B Medicare administrator, has established coding guidelines for the company's MammaPrint test. MammaPrint is Agendia's FDA-cleared breast cancer recurrence test, which has been reimbursed by payors since 2008.

Patients across the United States can now submit claims for the MammaPrint test directly to Palmetto GBA in California where the test results are analyzed. The coding guidelines for healthcare providers are available at the Centers for Medicare and Medicaid Services (CMS) website at http://www.cms.hhs.gov/mcd/viewlcd.asp?lcd_id=30376&lcd_version=5&show=all.

"Palmetto's decision to include MammaPrint in their reimbursement guidelines will provide greater access to this test for more women and their doctors when faced with difficult treatment decisions around breast cancer," said Dr. Richard Bender, Chief Medical Officer of Agendia.

About MammaPrint(R)

MammaPrint is the first and only breast cancer recurrence test cleared by the U.S. Food and Drug Administration (FDA). FDA clearance under the in vitro diagnostic multivariate index assay (IVDMIA) guidelines requires clinical and analytical validation and reporting systems to ensure that patient safety and efficacy are addressed. Highly accurate, MammaPrint identifies patients with early metastasis-patients who are likely to develop metastases within five years following surgery. Several authoritative studies have shown that chemotherapy particularly reduces early metastasis risk. In planning treatment, the MammaPrint test results, in addition to other clinical information and pathology tests, provide doctors with a clear rationale to evaluate the benefits of chemotherapy

All MammaPrint tests are conducted in Agendia's CLIA-accredited service laboratory. Breast cancer recurrence assays currently marketed by other manufacturers have not been subject to the rigorous FDA clearance process.

About Agendia

Agendia is at the forefront of the personalized medicine revolution, striving to bring more effective, individualized treatments within reach of patients. Building on a cutting-edge genomics platform for tumor gene expression profiling, the company's tests help physicians more accurately tailor cancer treatments. Agendia markets four products, with several new genomic tests under development. In addition, Agendia collaborates with pharmaceutical companies to develop highly effective personalized drugs in the area of oncology. The Company was awarded the 2008 North American Oncology Clinical Diagnostics Healthcare Innovation Award by Frost & Sullivan. Agendia is based in Huntington Beach, California, and in Amsterdam, The Netherlands.

    MEDIA CONTACTS:

    Hans Herklots                        Valerie Delva
    Head of Corporate Communications     Account Executive
    Agendia                              Ricochet Public Relations
    +31-20-462-1557 Office               +1-212-679-3300 x131 Office
    +31-620-083-509 Mobile               vdelva@ricochetpr.com
    hans.herklots@agendia.com

SOURCE Agendia B.V.


'/>"/>
SOURCE Agendia B.V.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. QMed, Inc. Reports July Medicare SNP Enrollments
2. Change in Medicare and Medicaid Legislation Creates Market for Antimicrobial Coatings In the U.S.
3. House and Senate Pass Medicare Legislation to Freeze 2008 Reimbursement for Therapeutic Radiopharmaceuticals at 2007 Levels
4. Medicare Coverage Recommended for In-Home Sleep Testing
5. MedicareCRM(TM) to Speak at IIR Medicare Advantage Congress
6. STAAR Surgicals Collamer(R) IOL Designated as a New Technology Intraocular Lens by the Centers for Medicare and Medicaid Services
7. Medicare Approves in Home Sleep Apnea Testing
8. Medtronic Unit to Pay $75 Million to Settle Whistleblower Medicare Fraud Case
9. Medicare Exemplary Provider Accreditation Awarded to Regenesis Biomedical
10. Arcadian Health Plan Addresses Medicare Doctor Payment Cuts
11. Netsmart Technologies Web Seminar Helps Behavioral Health Organizations Understand Electronic Prescribing and the Importance of New Medicare-Related E-Prescribing Legislation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... September 19, 2017 , ... A best-selling author and an ... “Grit” author Angela Duckworth and her team at Character Lab have joined Philadelphia’s ... international law firm with decades of experience supporting high-growth companies in the technology ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... outbreak is about to be eliminated, said Lyle Probst, President, CEO and Founder ... technologies different than other pathogen detection solutions, Probst said, “Sample preparation takes ...
(Date:9/19/2017)... ... September 19, 2017 , ... Molecular Devices, ... with Cytena GmbH to launch the CloneSelect™ Single-Cell Printer™ in North America. ... single cells and provide visual documentation of monoclonality for use in cell line ...
(Date:9/18/2017)... , ... September 18, 2017 , ... ... residues to produce biochar, briquettes, and torrefied wood is the topic of a ... , To characterize the potential economic viability of transportable biomass conversion facilities for ...
Breaking Biology Technology:
(Date:7/20/2017)... Delta (NYSE: DAL ) customers now can use fingerprints instead ... National Airport (DCA). ... Delta launches biometrics to board aircraft at Reagan Washington National Airport ... Delta,s biometric boarding pass experience that launched in ... the boarding process to allow eligible Delta SkyMiles Members who are enrolled ...
(Date:5/23/2017)... , May 23, 2017  Hunova, the first robotic gym for the ... been officially launched in Genoa, Italy . The first ... and the USA . The technology was developed ... market by the IIT spin-off Movendo Technology thanks to a 10 million ... News Release, please click: ...
(Date:4/24/2017)... -- Janice Kephart , former 9/11 Commission ... LLP (IdSP) , today issues the following statement: ... 6, 2017 Executive Order: Protecting the Nation ... instilled with greater confidence, enabling the reactivation of ... are suspended by until at least July 2017). ...
Breaking Biology News(10 mins):